✦ LIBER ✦

The preclinical safety evaluation of human monoclonal antibody against cytomegalovirus

✍ Scribed by Keiko Matsuzawa; Tamotsu Koyama; Shigeki Sugawara; Sunao Ikegawa; Satoshi Asano; Satoshi Sasaki; Takami Tomiyama; Yoshinori Kasahara; Yoshiaki Okamiya; Kyoko Inoue; Tomohiro Ohta; Tokutaro Makita

Book ID: 116118884
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 850 KB
Volume: 19
Category: Article
ISSN: 0272-0590
DOI: 10.1016/0272-0590(92)90024-c

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Generation of hybridomas producing human

Generation of hybridomas producing human monoclonal antibodies against human cytomegalovirus

✍ Yoh-ichi Matsumoto; Tohru Sugano; Chikako Miyamoto; Yasuhiko Masuho 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 457 KB

Production of Monoclonal Antibodies Agai

Production of Monoclonal Antibodies Against Phosphoprotein 65 from Human Cytomegalovirus

✍ Xu, Li-Jun ;Yao, Hang-Ping ;Fan, Jun ;Li, Dan ;Wu, Nan-Ping 📂 Article 📅 2007 🏛 Mary Ann Liebert 🌐 English ⚖ 270 KB

Evaluation of a surrogate antibody for p

Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody

✍ Janet Clarke; Will Leach; Susanne Pippig; Amita Joshi; Benjamin Wu; Robert House 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 387 KB

Preclinical safety testing of monoclonal

Preclinical safety testing of monoclonal antibodies: the significance of species relevance

✍ Chapman, Kathryn; Pullen, Nick; Graham, Mark; Ragan, Ian 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 370 KB

Generation of potent neutralizing human

Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells

✍ Ada Funaro; Giorgio Gribaudo; Anna Luganini; Erika Ortolan; Nicola Lo Buono; Eli 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 776 KB

Background: Human monoclonal antibodies (mAbs) generated as a result of the immune response are likely to be the most effective therapeutic antibodies, particularly in the case of infectious diseases against which the immune response is protective. Human cytomegalovirus (HCMV) is an ubiquitous oppo

Clinical evaluation (Phase I) of a human

Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: Safety and antiviral activity

✍ Eithan Galun; Norah A. Terrault; Rachel Eren; Arie Zauberman; Ofer Nussbaum; Dov 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 231 KB